African Americans experience higher prevalence and mortality rates from cancer in comparison to other minority groups. For example, the mortality rate for African American men with head and neck cancer is approximately two times greater than that of white men (ACS, 2022). There are a myriad of health disparities that influence the inferior health results observed in African American men with head and neck cancer. A variety of strategies may serve to decrease the mortality rate among African Americans with head and neck cancer. One strategy may be to increase the recruitment of African Americans to head and neck cancer clinical trials (CCTs) as this would provide additional access to novel treatments while also helping to create more effective treatments for this population. African Americans make up approximately 14% of the US population, and research shows that only 3.1% of participants in CCTs are African American (Loree et al., 2019). This is an issue as the underrepresentation of African Americans to CCTs limits the understanding of potential differences that may be critical for the development of more effective cancer treatments across population subgroups. As the participation of African Americans in CCTs is hindered by many facets—this rapid systematic review will investigate the evidence based barriers that impact the accrual of African Americans to CCTs. Consequently, a comprehensive plan will be created in which head and neck cancer institutions can use to implement the optimal strategies to increase accrual of African Americans in head and neck cancer clinical trials.
Recommended CitationHenao, Camilo, "Recommendations to Increase the Participation of African Americans to Head and Neck Cancer Clinical Trials: A Rapid Systematic Review" (2022). Master of Public Health Capstone Presentations. Presentation 422.